AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceHealth Care
Lewy Body DiseaseLewy Bodiesalpha-SynucleinParkinson DiseaseSynucleinsInclusion BodiesNeurofibrilsMultiple System AtrophyHallucinationsDementiaAlzheimer DiseaseMyoclonusBrainSupranuclear Palsy, ProgressiveAutopsyBoidaeSynaptophysinSubstantia NigraNeurodegenerative DiseasesEnkephalin, LeucineBrain StemNerve DegenerationArenavirusNeuropsychological TestsNeuronsbeta-SynucleinCognition DisordersNerve Tissue ProteinsCerebral CortexBiological MarkersImmunohistochemistryInclusion Bodies, ViralPeer Review, ResearchPublishingCopyrightPeriodicals as TopicAccess to InformationExtrapyramidal Tracts
Parkinson's2023Cerebrospinal fluid biomarkersAmyloidDementiasPlasma BiomarkersCandidate biomarkersDiagnosisParkinsonianIdentify biomarkersMild cognitiveClinicalFrontotemporal dementiaNeuronsCognitiveAmyotrophic lateral sProteinsDisordersDopamine deficiency in the brainFindingsSubstantia nigraNeurofibrillary tanglesClinicallyVascular DementiaAlzheimer DiseaseNeuronalParkinson DiseaseDetectDysfunctionSyndromesDiagnosticDementia researchParkinsonismResearchProgressionTypes of dementiaNeurodegenerative diseaseNormal pressure hydrSynapticTreatmentsMetabolicBrain diseasesAlpha-synucleinDepositsResearchers2018SymptomsCentersGeneticPathologyCharacteristicMolecular Neurodegeneration
Parkinson's71
  • Parkinson's Disease Biomarker Program. (wikipedia.org)
  • Although less known than Alzheimer's disease and Parkinson's disease, LBD is not a rare disorder. (nih.gov)
  • Also, LBD can occur alone or along with Alzheimer's or Parkinson's disease. (nih.gov)
  • There are two types of LBD-dementia with Lewy bodies and Parkinson's disease dementia. (nih.gov)
  • Over time, people with dementia with Lewy bodies or Parkinson's disease dementia may develop similar symptoms. (nih.gov)
  • In 1912, he discovered abnormal protein deposits that disrupt the brain's normal functioning in people with Parkinson's disease. (nih.gov)
  • Marian is interested in learning more about cognitive decline and behavioral changes in individuals with Parkinson's disease. (stanford.edu)
  • Her current studies focus on neurodegenerative processes, cognitive impairment, motor dysfunction, and modulators of disease severity in people aging with HIV infection, in Parkinson's disease, and alcohol use disorder. (stanford.edu)
  • At Dr. Poston's laboratory, Dr. Müller-Oehring is expanding her neuroimaging research to PET/MR aiming to identify biomarkers underwriting the functional status in Parkinson's disease. (stanford.edu)
  • Researchers from Lund University have discovered a promising biomarker for Parkinson's disease and other disorders that involve dopamine deficiency in the brain. (expresshealthcaremgmt.com)
  • The biomarker, called DOPA decarboxylase (DCC), was found to be elevated in individuals with Parkinson's disease and other dopamine-related diseases. (expresshealthcaremgmt.com)
  • Importantly, this biomarker can be measured in blood, making it a potential non-invasive tool for diagnosing Parkinson's disease. (expresshealthcaremgmt.com)
  • This groundbreaking research provides hope for improved diagnostics and personalized treatment for patients with Parkinson's disease and other dopamine-related disorders. (expresshealthcaremgmt.com)
  • Parkinson's disease (PD) is a quite common neurodegenerative disorder with a prevalence of approximately 1:800-1,000 in subjects over 60 years old. (frontiersin.org)
  • Research paper: Can we predict development of impulsive-compulsive behaviours in Parkinson's disease? (bmj.com)
  • Part of my research focuses on the aggregation of alpha-synuclein, a protein involved in dementia with Lewy bodies and Parkinson's disease. (isogen-lifescience.com)
  • Limited data compares clinical profiles of Lewy Body Dementia (LBD) with Alzheimer's disease (AD) and Parkinson's disease (PD). (iospress.com)
  • Furthermore, clinically we find that DLB is often diagnosed as AD, PD, or Parkinson's disease dementia (PDD) as there are many overlapping clinical features, dual diagnoses, or atypical presentations. (iospress.com)
  • Increased ceramide levels in the brain may be a unique feature of all types of Lewy body dementias, including LBD associated with Parkinson's disease. (neurosciencenews.com)
  • Nov. 17, 2023 Proteins misfolding and clumping together, a process known as aggregation, is a key feature seen in several neurological conditions, including Alzheimer's and Parkinson's diseases. (sciencedaily.com)
  • Nov. 20, 2023 Proteins that form clumps occur in many difficult-to-treat diseases, such as ALS, Alzheimer's, and Parkinson's. (sciencedaily.com)
  • for example, what is the role of a-synuclein in lewy bodies, which is shared with Parkinson's? (parkinson.ca)
  • Is Parkinson's disease the same or linked to Diffuse Lewy body disease? (parkinson.ca)
  • What about acetylcholine that impacts cognitive function, a common non-motor symptom in Parkinson's disease? (parkinson.ca)
  • Patient presented with known Parkinson's disease for continued care and requested for formal confirmation to increase disability benefits from the VA. Abnormal motor exam findings: distractible tremor, promotable dyskinesia, and deliberate bradykinesia. (mdsabstracts.org)
  • Baseline FP-CIT SPECT (DaTScan) severity correlates with medication use at 3 years in Parkinson's disease. (mdsabstracts.org)
  • Background Mild memory impairment, termed amnestic mild cognitive impairment (aMCI), is associated with rapid progression towards dementia in Parkinson's disease (PD). (researchgate.net)
  • Parkinson's disease (PD) is a progressive neurodegenerative disorder that leads to numerous impairments in motor function that compromise the ability to perform activities of daily living. (researchgate.net)
  • Background and purpose: Resting-state functional MRI (rs-fMRI) studies in Parkinson's disease (PD) patients with freezing of gait (FOG) have implicated dysfunctional connectivity over multiple resting-state networks (RSNs). (researchgate.net)
  • Digital health technologies can provide continuous monitoring and objective, real-world measures of Parkinson's disease (PD), but have primarily been evaluated in small, single-site studies. (researchgate.net)
  • Clinical Review of Smartphone Applications in Parkinson's Disease. (uci.edu)
  • Comprehensive subtyping of Parkinson's disease patients with similarity fusion: a case study with BioFIND data. (uci.edu)
  • Characteristics and Outcomes of Parkinson's Disease Individuals Hospitalized with COVID-19 in a New York City Hospital System. (uci.edu)
  • Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. (ucl.ac.uk)
  • Lipidomic techniques continue to provide evidence for their association in neurological diseases, including Parkinson's disease (PD) and Lewy body disease (LBD). (mdpi.com)
  • Measuring olfactory dysfunction shows promise as one of a number of nonmotor biomarkers that can be used to detect clinically manifest and prodromal Parkinson's disease (PD) and dementia with Lewy bodies (DLB) and to differentiate these from nonsynucleinopathies. (innovationscns.com)
  • Identifying nonmotor biomarkers for Parkinson's disease (PD) and dementia with Lewy body disease (DLB) presents an opportunity to detect the disease prior to widespread central nervous system (CNS) spread of Lewy type synucleinopathy (aSyn), with consequent severe dopaminergic neuronal loss in the substantia nigra and progression to motor and cognitive dysfunction. (innovationscns.com)
  • In a small study, researchers at the National Institutes of Health have found that positron emission tomography (PET) scans of the heart may identify people who will go on to develop Parkinson's disease or Lewy body dementia among those at-risk for these diseases. (nih.gov)
  • The findings, published in the Journal of Clinical Investigation and led by scientists at the National Institute of Neurological Disorders and Stroke (NINDS), part of NIH, may advance efforts to detect the earliest changes that years later lead to Parkinson's disease and Lewy body dementia. (nih.gov)
  • In 34 people with Parkinson's disease risk factors, researchers conducted PET scans of the heart to gain insight into levels of the neurotransmitter norepinephrine. (nih.gov)
  • They found that the scans could distinguish individuals who would later be diagnosed with Parkinson's or Lewy body dementia - both are brain diseases caused by abnormal deposits of the protein alpha-synuclein that form clumps known as Lewy bodies. (nih.gov)
  • Norepinephrine is derived from dopamine, which is deficient in the brains of people with Parkinson's disease. (nih.gov)
  • In the present study, the research team led by Dr. Goldstein found that at-risk individuals with low 18 F-dopamine-derived radioactivity in the heart were highly likely to develop Parkinson's or Lewy body dementia during long-term follow-up, compared to individuals with the same risk factors but with normal radioactivity. (nih.gov)
  • Heart and brain PET scans from a study participant who developed Parkinson's disease support a 'body first' progression. (nih.gov)
  • We have observed that an enzyme in cerebrospinal fluid and in blood is a useful marker for identifying all types of Parkinson's-related diseases with high accuracy,' says Oskar Hansson, who led the study. (lu.se)
  • In the current study, DCC was found to be elevated in individuals with Parkinson's disease as well as in people with other diseases that result in dopamine deficiency in the brain. (lu.se)
  • An important discovery is that this biomarker can be measured in blood, where it is significantly increased, especially in Parkinson's disease," says Oskar Hansson, a professor of neurology at Lund University and a consultant at Skåne University Hospital. (lu.se)
  • Increased neurofilament levels in biofluids, commonly used as a proxy for axonal degeneration in the brain, have been found in Parkinson's disease (PD), PD with dementia (PDD) and dementia with Lewy bodies (DLB), and correlate with MRI biomarkers. (biorxiv.org)
  • Members of the European Platform for Neurodegenerative Diseases (EPND) announced today that they will embark on a venture to establish a collaborative platform for efficient sample and data sharing, leveraging and linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's. (kcl.ac.uk)
  • There is currently a lack of available treatments that can prevent or modify the progression of neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (PD), which affect millions of people in Europe. (kcl.ac.uk)
  • Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by the loss of dopaminergic neurons and the accumulation of iron in the substantia nigra. (bvsalud.org)
  • RBD and associated comorbidities have recently been identified as one of the most specific and potentially sensitive risk factors for later development of any of the alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and other atypical parkinsonian syndromes. (ku.dk)
  • Several other sleep-related abnormalities have recently been identified in patients with RBD/Parkinson's disease who experience abnormalities in sleep electroencephalographic frequencies, sleep-wake transitions, wake and sleep stability, occurrence and morphology of sleep spindles, and electrooculography measures. (ku.dk)
  • Parkinson's disease. (neurologyadvisor.com)
  • The two clinical subgroups of Lewy body dementias, namely, dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), are differentiated by the chronology of cognitive symptoms relative to parkinsonism. (biomedcentral.com)
  • dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are distinguished by the temporal relationship between the onset of dementia and motor symptoms. (biomedcentral.com)
  • Although a similar clinical proteomic approach has been used to study Parkinson's disease (PD), few studies have focused on Lewy body dementias exclusively [ 21 ]. (biomedcentral.com)
  • Further, the Aβ42/Aβ40 and Aβ42/Aβ38 ratios showed increased accuracy compared to Aβ42 when distinguishing AD from dementia with Lewy bodies or Parkinson's disease dementia and subcortical vascular dementia, where all Aβs (including Aβ42) were decreased. (lu.se)
  • Testing an individual's tears for the presence of certain biomarkers could allow easier diagnosis of Parkinson's disease , a new study suggests. (medscape.com)
  • Assessing levels of certain proteins associated with Parkinson's disease - particularly α synuclein - in tears may be a reliable, inexpensive, and noninvasive test for the condition," lead author, Mark Lew, MD, Keck School of Medicine, University of Southern California, Los Angeles, told Medscape Medical News . (medscape.com)
  • Lew explained that identifying an easy-to-measure biomarker for Parkinson's would be very helpful, especially if it could be detected early in the disease course. (medscape.com)
  • While we can diagnose Parkinson's quite effectively in patients with later disease after they have developed motor symptoms, earlier diagnosis is problematic," he said. (medscape.com)
  • A test that could identify Parkinson's disease in patients with very early symptoms might in the future make it possible to start disease-modifying treatments much earlier, which could slow the disease course, he added. (medscape.com)
  • There are also many conditions which resemble Parkinson's disease but are not actually Parkinson's disease, and it would be very useful to have a test that distinguished these different conditions. (medscape.com)
  • We had the opportunity to work with some ophthalmologists who have previously found potential biomarkers for some other disorders in tears, so we thought we would look for Parkinson's biomarkers in tears as well. (medscape.com)
  • For the study, the researchers tested tears from patients with Parkinson's and age-matched controls for concentrations of several proteins associated with Parkinson's disease. (medscape.com)
  • The researchers analyzed the tear fluid collected for concentration of α synuclein, CC chemokine ligand 2 (CCL-2), and DJ-1 (Parkinson's disease protein 7). (medscape.com)
  • Results are so far available for 55 patients with Parkinson's disease of varying severity and 27 age- and sex-matched controls. (medscape.com)
  • He explained that α synuclein is found in many parts of the body, and in Parkinson's disease it tends to clump together in the oligomeric form, which become the toxic Lewy bodies characteristic of the condition. (medscape.com)
  • So our observation of lower levels of the monomeric form and higher levels of the oligomeric form seen in the tears of Parkinson's disease makes sense and is what we might expect. (medscape.com)
  • The researchers conclude: "To our knowledge this is the first report of tear collection and protein analysis as a possible non-invasive, inexpensive and reliable biomarker for Parkinson's. (medscape.com)
20233
  • 2023). DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. (expresshealthcaremgmt.com)
  • Nov. 16, 2023 Scientists have published new evidence that shows changes in brain network patterns that occur in early-stage Alzheimer's disease differ from those associated with normal aging. (sciencedaily.com)
  • Nov. 7, 2023 Researchers have discovered a link between obesity and neurodegenerative disorders like Alzheimer's disease. (sciencedaily.com)
Cerebrospinal fluid biomarkers2
  • The field of neurodegenerative dementias, particularly Alzheimer's disease (AD), has been revolutionized by the development of imaging and cerebrospinal fluid biomarkers and is on the brink of a new development: emerging plasma biomarkers. (medscape.com)
  • A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. (ucl.ac.uk)
Amyloid10
  • amyloid and tau NFT pathologies are all present, often diagnosed neuropathologically as Alzheimer disease (AD) with PD. (neurodegenerationresearch.eu)
  • Since the use of amyloid PET and other biomarkers for the diagnosis of AD, PD, and LBD are limited in clinical practice and since prognosis and management are distinct for each of these conditions, improved clinical methods in differentiating these groups to achieve accurate diagnoses are criticallyneeded. (iospress.com)
  • Here is an overview of the framework, which requires biomarker evidence of amyloid plaques (amyloid positivity) and neurofibrillary tangles (tau positivity), with evidence of neurodegeneration (neurodegeneration positivity) to support the diagnosis. (medscape.com)
  • The findings suggest that low levels of beta-amyloid protein and high levels of tau protein in cerebrospinal fluid are a 'signature' that is characteristic of Alzheimer's disease, and can also be found in most people with mild cognitive impairment, a condition that often precedes Alzheimer's disease dementia. (alz.org)
  • The results of CSF beta-amyloid and tau protein measurements do not stand alone as a single diagnostic test for Alzheimer's because they are seen in other diseases, too. (alz.org)
  • Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. (dzne.de)
  • These deposits, which accumulate when naturally-occurring proteins in the body fold into the wrong shape and stick together, are formed primarily of two proteins: amyloid-beta and tau. (neurodegenerationresearch.eu)
  • Alzheimer Disease Alzheimer disease causes progressive cognitive deterioration and is characterized by beta-amyloid deposits and neurofibrillary tangles in the cerebral cortex and subcortical gray matter. (msdmanuals.com)
  • In this study, we compared the detergent-soluble proteome via an 8-plex isobaric tag for relative and absolute quantitation (iTRAQ) analysis of pooled lysates from the prefrontal cortex (BA9) of DLB ( n = 19) and PDD ( n = 21) patients matched a priori for amyloid (total Aβ42) burden, semi-quantitative scores for Lewy bodies and neurofibrillary tangles together with age-matched control ( n = 21) subjects. (biomedcentral.com)
  • In conclusion, the largely similar proteome of DLB and PDD matched for amyloid burden suggests that variations in concomitant AD-related pathology, abnormal post-translational modifications or protein-protein interactions, defective intracellular trafficking or misfolding of proteins could play a part in driving the clinically observed differences between these two subgroups of Lewy body dementias. (biomedcentral.com)
Dementias5
  • In particular, we are studying longitudinal brain-behaviour relationships with a focus on cerebrovascular disease and less common dementias, such as Lewy Body Disease and frontotemporal degeneration, using clinical, neuropsychological, neuroimaging and genetic biomarkers. (sunnybrook.ca)
  • The Alzheimer's Disease Research Center at Mayo Clinic promotes research and education about healthy brain aging, mild cognitive impairment, Alzheimer's disease, Lewy body dementia, frontotemporal dementia, and other related dementias. (mayoclinic.org)
  • Lewy body dementias are the second most common cause of neurodegenerative dementia in the elderly after Alzheimer's disease (AD). (biomedcentral.com)
  • At present, there remains a debate on whether DLB and PDD are separate disease entities, or fall within the same spectrum of Lewy body dementias. (biomedcentral.com)
  • In addition to caring for patients with dementias, he researches the disease at the University of Pennsylvania. (medlineplus.gov)
Plasma Biomarkers1
  • Although molecular biomarkers are typically considered at the later stage of the clinical workup, the anticipated future availability of plasma biomarkers will probably change the timing of molecular biomarker assessment in patients with suspected cognitive impairment owing to AD. (medscape.com)
Candidate biomarkers2
  • thus, they are considered core candidate biomarkers. (nature.com)
  • Sen heads the Unit on Clinical and Translational Studies where her research aims to characterize critical inflammatory and metabolic pathways in uveitis and other immune-mediated eye diseases with the goal of identifying candidate biomarkers and novel mechanistic targets for therapeutic intervention. (nih.gov)
Diagnosis13
  • The disease lasts an average of five to seven years from the time of diagnosis to death, but the time span can range from two to 20 years. (nih.gov)
  • However, research attempting to establish the reliability of Aβ and tau as biomarkers has culminated in an amalgamation of contradictory results and theories regarding the biomarker concentrations necessary for an accurate diagnosis. (nature.com)
  • Due to the long prodromal period of AD, the potential for early diagnosis of AD is crucial to effectively utilize disease-modifying drugs. (nature.com)
  • BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer's disease, multiple sclerosis, and epilepsy. (diagnosticimaging.com)
  • Research on the diagnosis and management of dementia with Lewy bodies (DLB) has increased greatly in the past decade [ 1-11 ]. (iospress.com)
  • Research now recognizes the relationship between the cognitive-behavioral syndromic diagnosis (ie, the illness) and the etiologic diagnosis (the disease) - and the need to consider each separately when developing a diagnostic formulation . (medscape.com)
  • Once the clinician has a prioritized differential diagnosis of the brain disease or condition that is probably causing or contributing to the patient's signs and symptoms, they can then select appropriate assessments and tests, typically starting with a laboratory panel and brain MRI . (medscape.com)
  • The diagnosis revised to Lewy body dementia with functional overlay and severe behavioral disturbances. (mdsabstracts.org)
  • The biomarker-based diagnosis of Alzheimer's disease. (dzne.de)
  • Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. (dzne.de)
  • Increasing awareness about the symptoms and signs of LBD will help avoid such situations, says John Hsiao, M.D., chief of the diagnosis and biomarkers program in the division of neuroscience at NIA. (medlineplus.gov)
  • Clinical Utility of Genetic Testing in the Precision Diagnosis and Management of Pediatric Patients with Kidney and Urinary Tract Diseases. (cdc.gov)
  • The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here? (cdc.gov)
Parkinsonian1
  • They are characterized by the presence of cortical α-synuclein-positive Lewy bodies (LBs) and Parkinsonian extrapyramidal motor symptoms. (biomedcentral.com)
Identify biomarkers2
  • We conducted this in 428 individuals to identify biomarkers that can indicate whether a patient with motor disturbances or cognitive difficulties has damage to the dopamine system in the brain. (lu.se)
  • We propose that these findings may help identify biomarkers of individuals at high risk of subsequent conversion to parkinsonism. (ku.dk)
Mild cognitive1
  • The proposed new diagnostic criteria reflect the well-accepted idea of a continuum of Alzheimer's disease - from presymptomatic Alzheimer's, to mild cognitive impairment, to Alzheimer's dementia. (alz.org)
Clinical20
  • Dementia with Lewy bodies: clinical and biological aspects (1st ed. (wikipedia.org)
  • However, the role of these new biomarkers and molecular mechanisms in PD requires further experiments in vivo and in vitro and further clinical evidence. (frontiersin.org)
  • Current technological advancements in clinical and research settings have permitted a more intensive and comprehensive understanding of Alzheimer's disease (AD). (nature.com)
  • In this review, we consider the capabilities and limitations of fluid biomarkers collected from cerebrospinal fluid, blood, and oral, ocular, and olfactory secretions as diagnostic tools for AD, along with the impact of the integration of these biomarkers in clinical settings. (nature.com)
  • Researchers say gait could be a clinical biomarker for dementia subtypes. (neurosciencenews.com)
  • It is at the earliest stages of the disease that we hope to be able to eventually intervene with disease modifying treatments, when they become available, and for which we need participants for clinical trials now. (alz.org)
  • In patients with inconsistent subjective history reporting as compared to clinical exam findings and biomarkers it increases the complexity of management. (mdsabstracts.org)
  • Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. (dzne.de)
  • Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. (dzne.de)
  • Chiotis K, Dodich A, Boccardi M, Festari C, Drzezga A, Hansson O, Ossenkoppele R, Frisoni G, Garibotto V, Nordberg A. Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. (dzne.de)
  • Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. (uci.edu)
  • The role of tau in the pathological process and clinical expression of Huntington's disease. (ucl.ac.uk)
  • Enzyme replacement therapy (ERT) is indicated for patients with type 1 and type 3 Gaucher disease who exhibit clinical signs and symptoms of the disease, including anemia, thrombocytopenia, skeletal disease, or visceromegaly. (medscape.com)
  • The European Platform for Neurodegenerative Diseases (EPND) integrates existing initiatives to build, grow, and deliver a scalable and self-sustainable platform for storage and analysis of high-quality clinical samples and data collections. (kcl.ac.uk)
  • Despite robust research efforts to accelerate biomarker discovery, at this time there are few secure, accessible ways for clinical samples and data to be discovered and shared within the neurodegenerative disease research community. (kcl.ac.uk)
  • Thanks to funding from the Innovative Medicines Initiative (IMI), EPND will begin a five-year effort to establish a self-sustaining network that will support the discovery, harmonization, storage and analysis of high-quality clinical samples and data from neurodegenerative disease research. (kcl.ac.uk)
  • The generalisation of a deep learning dose calculation method (hereinafter referred to as TERMA-Monte Carlo network, T-MC net) was evaluated in clinical practice using intensity-modulated radiotherapy (IMRT) plans for various human body regions and multiple institutions, with the Monte Carlo (MC) algorithm serving as a benchmark.Approach. (bvsalud.org)
  • Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington's disease: a study of linked Swedish National Registries (2002-2019). (lu.se)
  • Learn more about Alzheimer's disease and related clinical trials. (medlineplus.gov)
  • OBJECTIVE: The diagnostic accuracy of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) must be improved before widespread clinical use. (lu.se)
Frontotemporal dementia3
  • Researchers from the Mayo Clinic in Rochester, MN, sought to investigate age-corrected brain MRE findings in subjects with Alzheimer disease, dementia with Lewy bodies, frontotemporal dementia, and normal pressure hydrocephalus, and determine the potential use as a differentiating biomarker in dementia subtypes. (diagnosticimaging.com)
  • Patients with Alzheimer disease and frontotemporal dementia showed decreased cerebral stiffness with regional softening of the frontal and temporal lobes. (diagnosticimaging.com)
  • Progranulin surfaced independently in the laboratories of Christine van Broeckhoven at the VIB-University of Antwerp, Belgium, and of Michael Hutton, then at the Mayo Clinic Jacksonville, Florida, as the gene for the tau-negative form of frontotemporal dementia 17 (FTLD-U). This highly familial disease frequently strikes people younger than 65 (see ARF related news story ). (alzforum.org)
Neurons3
  • Later, brain scans showed a loss of dopamine-producing neurons and the individual developed symptoms of the disease. (nih.gov)
  • Effects of mutant huntingtin in oxytocin neurons on non-motor features of Huntington's disease. (lu.se)
  • Dementia with Lewy bodies is chronic cognitive deterioration characterized by cellular inclusions called Lewy bodies in the cytoplasm of cortical neurons. (msdmanuals.com)
Cognitive4
  • AD pathogenesis is initially isolated to the limbic region in afflicted patients, but as the disease progresses to other neocortical areas, additional cognitive symptoms manifest and become apparent 3 . (nature.com)
  • This conference will bring together cutting-edge science with practical considerations for people experiencing cognitive issues and their families," says Ronald Petersen, M.D., Ph.D. , director of the Alzheimer's Disease Research Center at Mayo Clinic. (mayoclinic.org)
  • To access the full paper, "METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration," click here . (neurodegenerationresearch.eu)
  • Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington's disease patients. (lu.se)
Amyotrophic lateral s2
  • Through a tablet and microphone, investigators recently found that digital speech biomarkers may serve as a potentially beneficial objective measure of speech function for patients with amyotrophic lateral sclerosis (ALS). (neurologylive.com)
  • In contrast, the general theme emerging from progranulin genetics is that null mutations that slash protein levels in half cause familial FTLD-U, while milder missense mutations that cause a partial loss of function have a susceptibility role in Alzheimer's, amyotrophic lateral sclerosis, and perhaps Parkinson disease, van Broeckhoven said in her talk in Prague. (alzforum.org)
Proteins6
  • In our research, we analyse cerebrospinal fluid for up- or down regulated proteins, as this is an indication for several brain diseases. (isogen-lifescience.com)
  • We study the aggregation of proteins in relation to brain disorders, such as Alzheimer's disease. (isogen-lifescience.com)
  • Lewy Body Diseases (LBD) are characterized by abnormal clumps of proteins forming in the brain. (germanstrias.org)
  • They found that these parts of the brain are vulnerable because the body's defence mechanisms against the proteins partly responsible for Alzheimer's disease are weaker in these areas. (neurodegenerationresearch.eu)
  • Incredible as it may seem to a biomarker field plagued by inconsistent findings on blood tests for other proteins such as Aβ, all three groups reported the same overall result: it works just fine, thank you. (alzforum.org)
  • The gene itself is plenty complicated, and the six different granulin proteins resulting from it have physiological functions throughout the body. (alzforum.org)
Disorders4
  • The 2017 rewrite of the diagnostic criteria for DLB was led by Ian G. McKeith of Newcastle University and supported by The National Institute on Aging, National Institutes of Neurological Disorders and Stroke, the Lewy Body Dementia Association, the Lewy Body Society, Alzheimer's Association, Acadia Pharmaceuticals, Axovant Sciences, Banner Health, GE Healthcare, and Lundbeck. (wikipedia.org)
  • The criteria for diagnosing AD published by the National Institute on Neurological and Communicative Disorder and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) have been widely utilized by clinicians to distinguish between the symptoms present in "probable," "possible," or "definite" AD 5 . (nature.com)
  • Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. (mdsabstracts.org)
  • Because Lewy bodies occur in dementia with Lewy bodies and in Parkinson disease dementia, some experts think that the two disorders may be part of a more generalized synucleinopathy affecting the central and peripheral nervous systems. (msdmanuals.com)
Dopamine deficiency in the brain1
  • Is it possible that a single biomarker can detect all types of diseases related to dopamine deficiency in the brain? (lu.se)
Findings4
  • The findings were further confirmed in an additional group of 152 individuals, and blood plasma samples from 174 individuals also showed a significant increase in the biomarker. (expresshealthcaremgmt.com)
  • Case study to review functional exam findings in an abnormal Dopaminergic transporter scan positive Lewy body dementia patient. (mdsabstracts.org)
  • Using a larger sample size than in our previous study, we evaluated the relationship between olfactory dysfunction based on the University of Pennsylvania Smell Identification Test (UPSIT) to the clinicopathological findings in patients with PD (n=41), patients with incidental Lewy body disease (ILBD) (n=47), and controls with no neurodegenerative disease (n=137). (innovationscns.com)
  • The findings, published in the journal Science Advances , could help uncover the molecular origins of this devastating disease, and may be used to develop preventative treatments for at-risk individuals to be taken well before symptoms appear. (neurodegenerationresearch.eu)
Substantia nigra1
Neurofibrillary tangles2
  • It is possible to observe neuritic plaques and neurofibrillary tangles within the brain tissue of patients afflicted by Alzheimer's disease (AD). (nature.com)
  • and patients with dementia with Lewy bodies may have neuritic plaques and neurofibrillary tangles. (msdmanuals.com)
Clinically4
Vascular Dementia1
  • CSF AD biomarker profile was seen in 47% of patients with dementia with Lewy bodies (DLB), 38% in corticobasal degeneration (CBD), and almost 30% in frontotemporal lobar degeneration (FTLD) and vascular dementia (VaD). (neurology.org)
Alzheimer Disease3
  • Baseline CSF was collected from 512 patients with Alzheimer disease (AD) and 272 patients with other types of dementia (OD), 135 patients with a psychiatric disorder (PSY), and 275 patients with subjective memory complaints (SMC). (neurology.org)
  • In certain circumstances, neuropsychologic testing is helpful in differentiating DLB from Alzheimer disease and in establishing a baseline for future comparison. (medscape.com)
  • Patients with DLB may have changes on electroencephalography earlier than do patients with Alzheimer disease, but whether this difference is diagnostically useful is not clear. (medscape.com)
Neuronal1
  • Lewy bodies are spherical, eosinophilic, neuronal cytoplasmic inclusions composed of aggregates of alpha-synuclein, a synaptic protein. (msdmanuals.com)
Parkinson Disease8
Detect2
  • By clearly indicating that we may be able to detect brain changes related to Alzheimer's before we see outward symptoms of the disease, this article provides support for the current effort to revise the Alzheimer's disease diagnostic criteria that is being driven by the National Institute on Aging (NIA) and the Alzheimer's Association. (alz.org)
  • Interestingly, the non-symptomatic carriers had the same progranulin levels as their affected relatives, suggesting the ELISA may be able to detect preclinical disease and presymptomatic mutation carriers. (alzforum.org)
Dysfunction3
  • In sporadic PD patients, SNCA and mitochondrial dysfunction are the predominant components of Lewy bodies, and complex I is found to be defective in the cytoplasm in the SN ( Henchcliffe and Beal, 2008 ). (frontiersin.org)
  • These data add to the growing body of evidence supporting early olfactory dysfunction as a prodromal biomarker for the risk of developing PD and ILBD as a prodromal Lewy body disorder. (innovationscns.com)
  • Some of these nonmotor biomarkers include olfactory dysfunction, visual changes, and constipation. (innovationscns.com)
Syndromes2
Diagnostic5
  • In conclusion, this study suggested that five significantly downregulated mRNAs (MAPK8, CDC42, NDUFS1, COX4I1, and SDHC) and three significantly downregulated miRNAs (miR-126-5p, miR-19-3p, and miR-29a-3p) were potentially useful diagnostic markers in clinic, and lipid metabolism (especially non-alcoholic fatty liver disease pathway) and mitochondrial dysregulation may be the keys to biochemically detectable molecular defects. (frontiersin.org)
  • This review is a summary and reflection of the ongoing concerted efforts to establish fluid biomarkers as a diagnostic tool and implement them in diagnostic procedures. (nature.com)
  • Her goal is to advance our molecular understanding of these devastating diseases and to use this knowledge for the development of new diagnostic tools and treatments. (nih.gov)
  • This study aimed to determine whether CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios are better diagnostic biomarkers of AD during both predementia and dementia stages in comparison to CSF Aβ42 alone. (lu.se)
  • The discovery of viable diagnostic biomarkers for Lewy body dementia using machine learning algorithms. (lu.se)
Dementia research1
  • This programme will build a secure platform via a European node on the AD Workbench of the Alzheimer's Disease Data Initiative (ADDI), a medical research organisation committed to increasing interoperability of data platforms and empowering scientists to analyse data for new discoveries in dementia research. (kcl.ac.uk)
Parkinsonism1
  • However, there are complexities in clinicopathological correlates, with multiple neuropathologies contributing to dementia and many cases with Lewy body neuropathology without dementia or Parkinsonism [ 13-15 ]. (iospress.com)
Research13
  • New Research Consortium Gives Dementia with Lewy Bodies Its Due" (Press release). (wikipedia.org)
  • Despite the extensive research dedicated to deciphering AD pathogenesis and discovering novel drug treatments, the comorbid nature of this disease, along with other psychological and physiological complications, obstructs the ability to examine the therapeutic effectiveness of these methods. (nature.com)
  • For over 5 years, we use the CLARIOstar plate reader successfully for our biomarker assay research of neurodegenerative diseases. (isogen-lifescience.com)
  • We bought an extra FLUOstar Omega for our biomarker research. (isogen-lifescience.com)
  • Even though we aren't gathering in person during the pandemic, this event will be an opportunity to learn, gain a renewed sense of hope and remind this community that we are all in this together," says Angela Lunde of the Alzheimer's Disease Research Center at Mayo Clinic. (mayoclinic.org)
  • Research in the Alzheimer's Disease Research Center has led to the detection of biomarkers and advanced neuroimaging tests, in turn paving the way for potential new prevention therapies and treatments for early Alzheimer's disease. (mayoclinic.org)
  • Your holiday gift today will provide much-needed care and support to the millions of families facing Alzheimer's, while advancing critical research to help end this disease. (alz.org)
  • This is very well-done article, by a top-level research team, which uses very sophisticated mathematics for identifying and analyzing possible Alzheimer's disease biomarkers in cerebrospinal fluid (CSF). (alz.org)
  • This research was supported in part by JPND through the STRENGTH project , selected for support in the 2012 risk factors call , and the SOPHIA project , selected for support in the 2011 biomarkers call . (neurodegenerationresearch.eu)
  • This research was supported in part by JPND through the NeuroGem project, selected under the 2013 cross-disease analysis call , and the PROP-AD project , selected under the 2015 JPco-fuND call . (neurodegenerationresearch.eu)
  • Cukras' research investigates inherited retinal degenerations, known collectively as retinitis pigmentosa, a family of blinding eye diseases which currently lack therapy. (nih.gov)
  • Currently there is no cure for Parkinsons disease but UK and international research is ongoing. (parkinsonsdaily.com)
  • Research specific to dementia is important because the course of the disease is highly variable and uncertain. (parkinsonsdaily.com)
Progression5
  • However, the dearth of such treatments can be attributed to the fact that most therapeutic attempts are rendered ineffective due to the advanced progression of the disease. (nature.com)
  • Thus, in order for a drug to be successful in combating AD, the extent of disease progression at the time of treatment must be considered in tandem with the pathophysiological target and composition of the drug 4 . (nature.com)
  • Geronimo et al wrote that the trend may be due to 'the progression of MND [motor neuron disease] or the repeated administration of botulinum toxin for neck dystonia during this period. (neurologylive.com)
  • ERT sometimes is started in patients with type 2 GD, as often there can be a question regarding disease type and progression, and to delay may have significant impact on patient outcomes. (medscape.com)
  • Earlier this year, the same researchers behind the current study proposed that 'neurostatins' could be taken by healthy individuals in order to slow or stop the progression of Alzheimer's disease, in a similar way to how statins are taken to prevent heart disease. (neurodegenerationresearch.eu)
Types of dementia1
Neurodegenerative disease2
  • This study was conducted through the Arizona Study of Aging and Neurodegenerative Disease (AZSAND). (innovationscns.com)
  • Scientists wrestling the complexities of α-synuclein fluid biochemistry might be forgiven for looking with some envy to a different protein of the neurodegenerative disease spectrum. (alzforum.org)
Normal pressure hydr1
  • Patients with normal pressure hydrocephalus showed stiffening of the parietal, occipital, and sensorimotor regions and those with dementia with Lewy bodies did not show significant stiffness changes in any of the regions. (diagnosticimaging.com)
Synaptic1
Treatments4
  • The development of effective treatments requires biomarkers for early detection of disease in individuals, for assessing treatment efficacy, and for patient stratification. (kcl.ac.uk)
  • The results imply that healthy young individuals with an aberrant form of this specific gene signature may be more likely to develop Alzheimer's disease in later life, and would most benefit from preventative treatments, if and when they are developed for human use. (neurodegenerationresearch.eu)
  • Since the molecular origins of the disease have been unknown to date, it has been difficult to breed genetically modified mice or other animals that repeat the full pathology of Alzheimer's disease, which is the most common way for scientists to understand this or any disease in order to develop new treatments. (neurodegenerationresearch.eu)
  • While we don't really have such treatments at present, there are several promising therapies in trials and it is likely that there will be disease-slowing medications available down the line," he said. (medscape.com)
Metabolic7
  • PET scans work by using a radioactive tracer to visualize metabolic or biochemical processes in body organs. (nih.gov)
  • IKKβ signaling mediates metabolic changes in the hypothalamus of a Huntington's disease mouse model. (lu.se)
  • Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice. (lu.se)
  • This prospective cohort study assessed whether PD-related brain metabolic patterns may be used as biomarkers in isolated REM sleep behavior disorder. (neurologyadvisor.com)
  • NCT02984137 ) to determine whether PD-related brain metabolic patterns may be used as biomarkers in isolated RBD and to compare metabolic patterns derived from long-stand and de novo PD. (neurologyadvisor.com)
  • While scores for both de novo PD-related brain metabolic patterns and long-standing PD were higher at baseline for disease converters compared with nondisease converters, the larger effect size in de novo PD-related brain metabolic patterns suggested that there is a higher discriminability of future converters with de novo PD-related brain metabolic patterns compared with long-term PD. (neurologyadvisor.com)
  • The [de novo PD-related brain metabolic patterns] can be an efficient biomarker individually applicable in [isolated REM sleep behavior disorder]," the study authors wrote. (neurologyadvisor.com)
Brain diseases5
  • Early LBD symptoms are often confused with similar symptoms found in other brain diseases like Alzheimer's. (nih.gov)
  • Misdiagnosis of neurodegenerative brain diseases is a significant concern, as the symptoms can resemble each other. (expresshealthcaremgmt.com)
  • However, the marker was normal in other brain diseases such as Alzheimer's disease. (lu.se)
  • Since the symptoms of various neurodegenerative brain diseases resemble each other, there is a significant risk of misdiagnosis and thus improper treatment. (lu.se)
  • Moreover, I believe that in the future, different brain diseases will be treated even before the symptoms become apparent, and blood markers will be essential in identifying the right individuals in a simple and cost-effective manner. (lu.se)
Alpha-synuclein3
Deposits3
Researchers5
  • The Dementia with Lewy Bodies Consortium (DLB Consortium or DLBC) is an international multidisciplinary collaboration of researchers interested in the dementia with Lewy bodies. (wikipedia.org)
  • The researchers also found that 36 percent of cognitively normal people in the study had the 'Alzheimer's signature' biomarkers in their spinal fluid at similar levels to people with Alzheimer's disease. (alz.org)
  • Researchers have discovered a gene signature in healthy brains that echoes the pattern in which Alzheimer's disease spreads through the brain much later in life. (neurodegenerationresearch.eu)
  • What researchers have long wondered is why certain parts of the brain are more vulnerable to Alzheimer's disease than others. (neurodegenerationresearch.eu)
  • When compared with tissue from Alzheimer's patients, the researchers found that this same pattern is repeated in the way the disease spreads in the brain. (neurodegenerationresearch.eu)
20181
Symptoms5
  • To be effective in disease modification, therapies will require testing and application in patients with only mild symptoms. (neurodegenerationresearch.eu)
  • LBD is a progressive disease, meaning symptoms start slowly and worsen over time. (nih.gov)
  • In this way, we could see how many of those people who have the biomarker signature but do not have symptoms go on to get Alzheimer's disease dementia. (alz.org)
  • However, some cases do not fit precisely into one of these categories, and the disease should be viewed as a spectrum of symptoms. (medscape.com)
  • So if a person's health care provider is treating their symptoms but not the disease, a patient could get very sick. (medlineplus.gov)
Centers1
  • Centers for Disease Control and Prevention. (cdc.gov)
Genetic2
  • Ultimately, this approach envisions what is now common practice in heart disease, where early signs of risk - blood pressure, cholesterol, genetic markers - can be detected and treated to reduce heart attacks or strokes later on. (alz.org)
  • Gaucher disease is a rare genetic disorder characterized by the deposition of glucocerebroside in cells of the macrophage-monocyte system. (medscape.com)
Pathology1
  • Early white matter pathology in the fornix of the limbic system in Huntington disease. (lu.se)
Characteristic1
  • Degeneration in Alzheimer's disease follows a characteristic pattern: starting from the entorhinal region and spreading out to all neocortical areas. (neurodegenerationresearch.eu)
Molecular Neurodegeneration1